Results 131 to 140 of about 905,676 (332)
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source
The anti-atherogenic effects of thiazolidinediones [PDF]
, 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced
Honisett, Suzy +2 more
core
Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis. [PDF]
, 1974 H F Hill +7 more
openalex +1 more source
Arthritis Care &Research, EarlyView.Objective Gastrointestinal perforation (GIP) is a rare and life‐threatening safety concern associated with JAK inhibitors (JAKi). We aimed to review the evidence regarding the risk of GIP associated with the use of JAKi in patients with rheumatoid arthritis (RA) using a systematic review and network meta‐analysis approach.
Thipsukhon Sathapanasiri +7 more
wiley +1 more source
Treating Rheumatoid Arthritis yesterday and today [PDF]
, 2004 Rheumatoid arthritis is a chronic, systemic inflammatory disorder that mainly affects joints. It is the most common form of inflammatory joint disease, and the second commonest joint disease, osteoarthritis being the commonest.
Mallia, Carmel
core
Arthritis Care &Research, Accepted Article.Background While treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change.
Austin Barry +16 more
wiley +1 more source
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]
, 2009 The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core +2 more sources
Chronic Opioids in Gout: A Matched Cohort Study from the Veteran's Health Administration
Arthritis Care &Research, Accepted Article.Objective Though used frequently to treat flare, risk of chronic opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed chronic opioids over time.
Lindsay N. Helget +7 more
wiley +1 more source
Targeting RAGE with Nanobodies for Molecular Imaging of Cancers and Alzheimer's Disease
Advanced Biology, EarlyView.RAGE‐specific nanobodies were isolated via phage display and characterized by ELISA, cell ELISA, and SPR. In vivo imaging in renal carcinoma and Alzheimer's disease mouse models demonstrated that NbF8, the highest‐affinity clone, selectively targeted RAGE‐overexpressing tumors and brain tissues, highlighting its potential as a molecular imaging agent ...
Guangfeng Liang +13 more
wiley +1 more source
Advanced Biology, EarlyView.Extracellular vesicles (EVs) play a dual role in diagnostics and therapeutics, offering innovative solutions for treating cancer, cardiovascular, neurodegenerative, and orthopedic diseases. This review highlights EVs’ potential to revolutionize personalized medicine through specific applications in disease detection and treatment.
Farbod Ebrahimi +4 more
wiley +1 more source